The SURPASS trials (studying tirzepatide for diabetes) showed approximately 5 to 13 percent weight loss over 40 to 52 weeks, compared to 16 to 22.5 percent in the SURMOUNT obesity trials
Precise, not one-size-fits-all
The NHS emphasises lifestyle modification as a first-line approach for metabolic health, and optimising GLP-1 function through natural means aligns with this evidence-based strategy
International journal of reproductive biomedicine
Ghrelin, an appetite stimulating hormone derived from the stomach, has been found to be expressed in all types of TBC together with its receptor growth hormone secretagogue receptor (GSHR) [119] and the ghrelin O-acetyltransferase (GOAT) necessary for post-transcriptionally active ghrelin
There is currently no FDA-approved oral tirzepatide, so any pill marketed as such is likely unsafe or unregulated